Literature DB >> 17066156

Antibiotic therapy for Crohn's disease: a review.

Simon Lal1, A Hillary Steinhart.   

Abstract

Increasing evidence suggests that gut bacteria play a pathogenic role in Crohn's disease (CD), providing a rationale for the use of antibiotics in the primary treatment of the disease. While there are data to suggest that antibiotics may be effective in treating active luminal, particularly colonic, and/or perianal CD, evidence for their use in these settings is hampered by the lack of well-designed, adequately powered, placebo-controlled trials. Furthermore, although nitroimidazole antibiotics have been shown to reduce postoperative recurrence following ileocolonic resection, their use is limited by side effects. There is a current need for rigorous multicentre studies looking into the role of antibiotics in treating perianal and luminal CD, as well as a need for the large-scale assessment of novel antibiotics, with low systemic absorption, which may improve patient tolerance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17066156      PMCID: PMC2660793          DOI: 10.1155/2006/250490

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  61 in total

1.  Preliminary study of ciprofloxacin in active Crohn's disease.

Authors:  George L Arnold; Mary R Beaves; Vladimir O Pryjdun; William J Mook
Journal:  Inflamm Bowel Dis       Date:  2002-01       Impact factor: 5.325

Review 2.  Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease?

Authors:  R Balfour Sartor
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease.

Authors:  Christel Neut; Philippe Bulois; Pierre Desreumaux; Jeanne-Marie Membré; Emmanuel Lederman; Luc Gambiez; Antoine Cortot; Pierre Quandalle; Herbert van Kruiningen; Jean-Fredéric Colombel
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

4.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

5.  Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.

Authors:  B Kleessen; A J Kroesen; H J Buhr; M Blaut
Journal:  Scand J Gastroenterol       Date:  2002-09       Impact factor: 2.423

6.  Open label trial of oral clarithromycin in active Crohn's disease.

Authors:  K Leiper; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

7.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

8.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

9.  Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.

Authors:  A Hillary Steinhart; Brian G Feagan; Cindy J Wong; Margaret Vandervoort; Shelley Mikolainis; Kenneth Croitoru; Ernest Seidman; Desmond J Leddin; Alain Bitton; Eric Drouin; Albert Cohen; Gordon R Greenberg
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

10.  Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice.

Authors:  H C Rath; M Schultz; R Freitag; L A Dieleman; F Li; H J Linde; J Schölmerich; R B Sartor
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

View more
  9 in total

Review 1.  [Diseases in gastroenterology].

Authors:  A Göke; B Göke
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

Review 2.  Microbial host interactions in IBD: implications for pathogenesis and therapy.

Authors:  R Balfour Sartor; Marcus Muehlbauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

3.  A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice.

Authors:  Tyson R Chiaro; Ray Soto; W Zac Stephens; Jason L Kubinak; Charisse Petersen; Lasha Gogokhia; Rickesha Bell; Julio C Delgado; James Cox; Warren Voth; Jessica Brown; David J Stillman; Ryan M O'Connell; Anne E Tebo; June L Round
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

Review 4.  IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.

Authors:  Doha Anka Idrissi; Nezha Senhaji; Asmae Aouiss; Loubna Khalki; Youssef Tijani; Nabil Zaid; Fatima Zahra Marhoume; Abdallah Naya; Mounia Oudghiri; Mostafa Kabine; Younes Zaid
Journal:  Arch Pharm Res       Date:  2021-01-04       Impact factor: 4.946

Review 5.  The intestinal microbiota and chronic disorders of the gut.

Authors:  Andrew W DuPont; Herbert L DuPont
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-16       Impact factor: 46.802

6.  Managing the risks of IBD therapy.

Authors:  Cynthia H Seow; Shanika de Silva; Gilaad G Kaplan; Shane M Devlin; Subrata Ghosh; Remo Panaccione
Journal:  Curr Gastroenterol Rep       Date:  2009-12

Review 7.  Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.

Authors:  Mario Matijašić; Tomislav Meštrović; Mihaela Perić; Hana Čipčić Paljetak; Marina Panek; Darija Vranešić Bender; Dina Ljubas Kelečić; Željko Krznarić; Donatella Verbanac
Journal:  Int J Mol Sci       Date:  2016-04-19       Impact factor: 5.923

Review 8.  Mycobacterium avium subspecies paratuberculosis: A possible causative agent in human morbidity and risk to public health safety.

Authors:  Mary Garvey
Journal:  Open Vet J       Date:  2018-05-19

9.  Machine Learning Can Predict the Probability of Biologic Therapy in Patients with Inflammatory Bowel Disease.

Authors:  David Schöler; Karel Kostev; Maximilian Peters; Cosmin Zamfir; Agnieszka Wolk; Christoph Roderburg; Sven H Loosen
Journal:  J Clin Med       Date:  2022-08-05       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.